Aquilo Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Aquilo Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,499,970	Closed	-$17M	–	16
2020 Q1	$17M	Buy	1,499,970 +333,234	+29%	+$4.75M	6.63%	5
2019 Q4	$15.3M	Buy	1,166,736 +215,209	+23%	+$2.26M	5.75%	5
2019 Q3	$8.57M	Hold	951,527	–	–	6.04%	9
2019 Q2	$9.38M	Hold	951,527	–	–	3.26%	9
2019 Q1	$9.67M	Hold	951,527	–	–	4.28%	9
2018 Q4	$6M	Buy	951,527 +358,725	+61%	+$3.19M	2.91%	9
2018 Q3	$7.83M	Buy	+592,802	New	+$6.87M	3.27%	10

Other funds holding XENE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Aquilo Capital Management's XENE Position: Q2 2020 in Review

Aquilo Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2020, closing a stake of 1,499,970 shares — an estimated $17M sold.

Aquilo Capital Management first reported a position in XENE in Q3 2018 and held it in 7 quarters. The position peaked at $17M in Q1 2020. 79 funds tracked by Wall St. Rank hold XENE as of Q2 2020.

Aquilo Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Aquilo Capital Management sold 1,499,970 Xenon Pharmaceuticals shares in Q2 2020, an estimated $17M.
Aquilo Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 7 quarters.
Aquilo Capital Management's Xenon Pharmaceuticals position peaked at $17M in Q1 2020.
79 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2020.

Based on Aquilo Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.